270 related articles for article (PubMed ID: 7745234)
21. [Clinical picture of differentiated thyroid carcinoma in the T1 stage].
Czarniecka A; Włoch J; Lange D
Wiad Lek; 2001; 54 Suppl 1():225-33. PubMed ID: 12182030
[TBL] [Abstract][Full Text] [Related]
22. [Differentiated thyroid carcinoma, 1972-1992. Follow-up, detection of recurrences and prognostic factors].
Obiols G; Simó R; Burgos R; Tresserras R; Galofré P; Masmiquel L; Hernández C; Mesa J
Med Clin (Barc); 1997 Nov; 109(19):738-43. PubMed ID: 9470182
[TBL] [Abstract][Full Text] [Related]
23. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
Zöphel K; Wunderlich G; Smith BR
Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
[TBL] [Abstract][Full Text] [Related]
24. The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer.
Wu LJ; Chen KY; Chi KH; Chen SY; Liang MJ; Shiau CY; Wang LW; Liu YM; Chow KC; Yen SH
Jpn J Clin Oncol; 1998 Dec; 28(12):729-32. PubMed ID: 9879289
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
27. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Tisi E; Lissoni P; Angeli M; Arrigoni C; Corno E; Cassina E; Ballabio D; Benenti C; Barni S; Tancini G
Cancer; 1992 May; 69(10):2458-62. PubMed ID: 1314691
[TBL] [Abstract][Full Text] [Related]
28. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
29. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
30. Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer.
Murakami S; Sakata H; Tsuji Y; Okubo K; Hamada S; Hirayama R
Dig Surg; 2002; 19(1):9-13; discussion 14. PubMed ID: 11961349
[TBL] [Abstract][Full Text] [Related]
31. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
32. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
33. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
34. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
Schroeder TJ; Helling T; McKenna RM; Rush D; Jeffrey JR; Brewer B; Martin LA; Traylor D; Fisher RA; First MR
Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
[TBL] [Abstract][Full Text] [Related]
35. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
36. Blood thyroglobulin and TSH receptor mRNA detection by RT-PCR in the follow-up of differentiated thyroid cancer patients.
Torosian L; Manrique G; Alvarez B; Lago G; Roca R; Belzarena C
Rev Esp Med Nucl; 2010; 29(3):109-13. PubMed ID: 20399540
[TBL] [Abstract][Full Text] [Related]
37. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome.
Haq M; Harmer C
Clin Endocrinol (Oxf); 2005 Jul; 63(1):87-93. PubMed ID: 15963067
[TBL] [Abstract][Full Text] [Related]
38. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
39. Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.
Koukkou E; Panayiotidis P; Thalassinos N
J Endocrinol Invest; 1995 Apr; 18(4):253-7. PubMed ID: 7560805
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
